Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel
disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response …

Background Loss of response to anti‐TNF agents is a common clinical problem. Dose
escalation may be effective for reestablishing clinical response in Crohn's disease (CD) …

Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody
concentrations in individuals to guide treatment decisions. In patients with Crohn disease …

Inflammatory bowel disease (IBD) treatment targets have progressed over time from clinical
response to clinical and endoscopic remission. Several data have shown a positive …

Background The availability of an infliximab ELISA for measuring the originator drug
Remicade and its biosimilars, such as Remsima and Inflectra (CT-P13), would facilitate the …

Highlights•Biologics are effective, but expensive, therapies for inflammatory bowel
disease.•Therapeutic drug monitoring reduces biologic costs through better drug …

Aims Development of a self‐sampling method for therapeutic drug monitoring (TDM) of
biologicals will enhance TDM implementation in routine care and pharmacokinetic …

Introduction Using therapeutic drug monitoring [TDM] in adult patients with inflammatory
bowel disease [IBD] remains controversial. We conducted a systematic review and meta …

This study of the use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α)
inhibitors in the management of Crohn's disease concluded that more evidence is required …

Objectives: The pharmacokinetics of infliximab (IFX) is highly variable in children with Crohn
disease (CD), and a one-size-fits-all approach to dosing is inadequate. Model-based drug …